Feature

Sequencing Therapies in Non-Hodgkin Lymphomas

Share

  • 1

    BTK inhibitors stop B-cell growth by inhibiting BTK enzyme.

  • 2

    Bispecific antibodies engage T-cells to kill B-cells.

  • 3

    CRS common after CAR T-cell therapy; first symptom is fever.

  • 4

    Monitoring for toxicities is crucial in advanced therapies.

  • 5

    Patient factors influence therapy sequencing decisions.

  • 6

    Palliative care improves quality of life and symptom management.

  • 7

    Logistical planning is vital for therapy administration.

Original Source(s)

Sequencing Therapies in Non-Hodgkin Lymphomas

  • by F. Brianne Buchanan, PA-C, Tatjana Grgic, PharmD, BCOP, CPP

  • February 27, 2026

  • 9 min

Related Content

Novel Therapies and Multidisciplinary Strategies in Metastatic Triple-Positive Breast Cancer

United in Care at JADPRO Live 2025

Management of Ocular Toxicity in Patients Receiving Belantamab Mafodotin

While significant strides have been made in the treatment of multiple myeloma, treatment options remain limited and definite, and most patients ultimately succumb to their disease. The urgency for mor...